Australian scientists have discovered how the immune system can control melanoma, a mechanism which could be used to enhance cancer treatments.
Published today in Nature, Peter Doherty Institute for Infection and Immunity (Doherty Institute) and Telethon Kids Institute researchers investigated the role of a particular immune cell, tissue-resident memory T (TRM) cells, in controlling melanoma.
TRM cells were able to control the tumour in the mice for the life of the animal, which is likely to equate to decades of protection in humans.
University of Melbourne PhD student, Simone Park from the Doherty Institute, created an imaging model to study TRM cells’ and melanoma in a mouse model.
“Using a special microscope, we could see individual melanoma cells sitting in the skin of the mouse, and could watch the T cells move through the skin, find the melanoma cells and control the growth of those cells,” Ms Park explained.
One of the main issues for cancer patients is that there is always a risk that the tumour can come back years later, after surgery or chemotherapy.
Previous research has shown that small numbers of cancer cells persist in the body after treatment and that the immune system probably keeps the cancer cells under control but this study in mice could study the immune system directly. This is work that could never be done in people.
“I was able to see through moving images that these TRM cells are important for maintaining the control of the tumour cells; if you remove the TRM cells you have a break in that control and the cancer can start to grow back again,” Ms Park said.
“If you could make more of these TRM cells through immunotherapies, or enhance the activity of those that are already there in some way, you could boost anti-tumour immunity.”
Senior author on the paper, University of Melbourne Associate Professor Thomas Gebhardt, Laboratory Head at the Doherty Institute, said an increase of TRM cells has already been associated with better outcomes in cancer patients, but the way they work to suppress tumours has remained unknown.
“The principal of cutting-edge immunotherapies currently in clinical practise is that they generate a T-cell response. But if we can hone in on one type of T-cell – the TRM cells specifically, we could have an even bigger impact on stopping cancers from coming back,” Associate Professor Gebhardt said.
“We now have a much better understanding of which T-cells are important in controlling skin cancers and how those cells are working but there is still much more work to do to make these cells work even better,” Associate Professor Gebhardt said.
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Nelson dad's life cut short after a melanoma was misdiagnosedon December 10, 2019 at 8:36 am
"It just hit me all of a sudden when I was there, Pete's not going to be here for her first day." Dixon's partner Pete Adams died from melanoma last July, more than three years after he was told a ...
- Melanoma Therapeutics Market To Reap Excessive Revenues by 2020-2029on December 9, 2019 at 9:54 pm
Dec 10, 2019 (WiredRelease via COMTEX) -- An extensive and elaborate primary research on Global Melanoma Therapeutics Market report sheds light on numerous facets such as growth factors, statistical ...
- Image of the Day: Melanoma Neural Networkon December 9, 2019 at 5:54 am
Researchers are presenting new images from their deep neural network that analyzes melanoma cells at this year’s American Society for Cell Biology / EMBO meeting, which started Saturday (December 7).
- Melanoma Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019 – 2026on December 9, 2019 at 1:12 am
Melanoma is one of the major types of skin cancer that develops from pigment-containing cells called melanocytes. Malignant tumors are formed as a result of rapid multiplication of skin cells occurs ...
- Blue light-triggered optogenetic system for treating uveal melanomaon December 6, 2019 at 7:19 am
Uveal melanoma is the most common intraocular primary malignancy in adults and has been considered a fatal disease for decades. Optogenetics is an emerging technique that can control the activation of ...
- Melanoma Therapeutics Market Expert Reviews & Analysis 2019 Along With Study Reportson December 6, 2019 at 5:00 am
Dec 06, 2019 (Market Insight Reports via COMTEX) -- Global Melanoma Therapeutics Market 2019:This report tracks the major market events including development trends, mergers & acquisitions and the ...
- Reply to: ‘IMPRES does not reproducibly predict response to immune checkpoint blockade therapy in metastatic melanoma’on December 5, 2019 at 8:23 am
All prices are NET prices. VAT will be added later in the checkout. All data analyzed in this manuscript are publicly available, and the accessions or web links to each dataset are provided either in ...
- Tel Aviv Professor receives Young Investigator Award for contributions in melanoma researchon December 4, 2019 at 9:50 pm
Tel Aviv University's Prof. Carmit Levy received the prestigious Young Investigator Award at the 16th International Congress of the Society for Melanoma Research, held November 20-23 in Salt Lake City ...
- Immunotherapy leads the way for melanoma treatmenton December 4, 2019 at 2:06 pm
Only a few months after she retired in October 2018, Lynn Walker knew something was wrong with her health. Without any prior history of skin cancers, she learned that she had an advanced form of ...
- Approaches to Stage II and III Melanoma: Recent Research Contexton December 1, 2019 at 12:52 am
This paper explores an important and topical question in melanoma management: what is the role for adjuvant therapy in resected stage II and III melanoma? Targeted therapy and immune checkpoint ...
via Bing News